(IDYA) Ideaya Biosciences - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.605m USD | Total Return: 55.8% in 12m
Avg Turnover: 24.9M
Qual. Beats: 0
Rev. Trend: 41.6%
Qual. Beats: 0
Warnings
High Debt while negative Cash Flow
Altman Z'' -9.21 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
IDEAYA Biosciences, Inc. is a clinical-stage precision medicine company focused on targeted oncology therapeutics. The firm utilizes molecular diagnostics to identify specific patient populations, primarily targeting synthetic lethality-a biological concept where the simultaneous deficiency of two genes leads to cell death, while a deficiency in only one does not. This approach aims to minimize damage to healthy tissue by exploiting specific genetic vulnerabilities in cancer cells.
The company’s pipeline includes several high-priority candidates, most notably Darovasertib, a PKC inhibitor currently in clinical trials for uveal melanoma. Other assets include IDE397, a MAT2A inhibitor for MTAP-deleted tumors, and various programs targeting HRD-associated mutations and WRN helicase. IDEAYA leverages a proprietary drug discovery platform integrating CRISPR-based target discovery and machine-learning engines to accelerate development.
The business model relies heavily on strategic partnerships with major pharmaceutical entities, including GlaxoSmithKline, Pfizer, and Gilead Sciences, to co-develop and commercialize its pipeline. Biotechnology firms in this stage typically require substantial research and development expenditure and often utilize these collaborations to offset clinical trial costs and gain access to established distribution networks. Examining the historical performance of these partnerships on ValueRay can provide deeper context on the companys valuation.
Headquartered in South San Francisco, IDEAYA operates within the biotechnology sector, where value is primarily driven by clinical trial milestones and regulatory approvals. Its diverse portfolio of first-in-class small molecules and antibody-drug conjugates positions it as a specialized player in the precision medicine landscape.
- Darovasertib clinical trial data readouts drive valuation in uveal melanoma markets
- Strategic partnerships with GSK and Pfizer validate platform and provide capital
- Pipeline progression of MAT2A and WRN inhibitors influences long-term growth prospects
- High research and development expenses necessitate periodic dilutive secondary equity offerings
- Regulatory approval timelines for precision oncology candidates dictate near-term stock volatility
| Net Income: -140.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA 15.81 > 1.0 |
| NWC/Revenue: 280.2% < 20% (prev 9.39k%; Δ -9.11k% < -1%) |
| CFO/TA -0.08 > 3% & CFO -85.9m > Net Income -140.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (88.7m) vs 12m ago 0.39% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 21.14% > 50% (prev 0.64%; Δ 20.51% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.61 (Total Current Assets 696.1m - Total Current Liabilities 64.8m) / Total Assets 1.03b |
| B: -0.81 (Retained Earnings -835.1m / Total Assets 1.03b) |
| C: -0.17 (EBIT TTM -183.5m / Avg Total Assets 1.07b) |
| D: -8.98 (Book Value of Equity -835.6m / Total Liabilities 93.1m) |
| Altman-Z'' = -9.21 = D |
As of May 24, 2026, the stock is trading at USD 29.54 with a total of 568,449 shares traded.
Over the past week, the price has changed by +3.15%,
over one month by -8.11%,
over three months by -9.37% and
over the past year by +55.78%.
Ideaya Biosciences has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy IDYA.
- StrongBuy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 52.8 | 78.6% |
P/S = 11.5642
P/B = 2.7794
Revenue TTM = 225.3m USD
EBIT TTM = -183.5m USD
EBITDA TTM = -178.9m USD
Long Term Debt = 28.2m USD (estimated: total debt 28.6m - short term 350k)
Short Term Debt = 350k USD (from shortTermDebt, last quarter)
Debt = 28.6m USD (from shortLongTermDebtTotal, last quarter) (leases 28.6m already included)
Net Debt = -642.6m USD (calculated: Debt 28.6m - CCE 671.2m)
Enterprise Value = 1.96b USD (2.61b + Debt 28.6m - CCE 671.2m)
Interest Coverage Ratio = unknown (Ebit TTM -183.5m / Interest Expense TTM 0.0)
EV/FCF = -22.32x (Enterprise Value 1.96b / FCF TTM -87.9m)
FCF Yield = -4.48% (FCF TTM -87.9m / Enterprise Value 1.96b)
FCF Margin = -39.03% (FCF TTM -87.9m / Revenue TTM 225.3m)
Net Margin = -62.17% (Net Income TTM -140.1m / Revenue TTM 225.3m)
Gross Margin = unknown ((Revenue TTM 225.3m - Cost of Revenue TTM 4.60m) / Revenue TTM)
Tobins Q-Ratio = 1.90 (Enterprise Value 1.96b / Total Assets 1.03b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 28.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -144.9m (EBIT -183.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.74 (Total Current Assets 696.1m / Total Current Liabilities 64.8m)
Debt / Equity = 0.03 (Debt 28.6m / totalStockholderEquity, last quarter 937.3m)
Debt / EBITDA = 3.59 (negative EBITDA) (Net Debt -642.6m / EBITDA -178.9m)
Debt / FCF = 7.31 (negative FCF - burning cash) (Net Debt -642.6m / FCF TTM -87.9m)
Total Stockholder Equity = 1.00b (last 4 quarters mean from totalStockholderEquity)
RoA = -13.14% (Net Income -140.1m / Total Assets 1.03b)
RoE = -7.62% (Net Income TTM -140.1m / Total Stockholder Equity 1.84b)
RoCE = -9.83% (EBIT -183.5m / Capital Employed (Equity 1.84b + L.T.Debt 28.2m))
RoIC = -19.49% (negative operating profit) (NOPAT -144.9m / Invested Capital 743.6m)
WACC = 9.05% (E(2.61b)/V(2.63b) * Re(9.15%) + D(28.6m)/V(2.63b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 14.62%
[DCF] Fair Price = unknown (Cash Flow -87.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.19 | # QB: 0
Revenue Correlation: 41.57 | Revenue CAGR: 96.46% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.06 | Chg30d=-6.47% | Revisions=-67% | Analysts=15
EPS next Quarter (2026-09-30): EPS=-1.10 | Chg30d=-9.16% | Revisions=-67% | Analysts=15
EPS current Year (2026-12-31): EPS=-4.43 | Chg30d=-11.77% | Revisions=-69% | GrowthEPS=-246.2% | GrowthRev=-86.6%
EPS next Year (2027-12-31): EPS=-3.70 | Chg30d=-8.98% | Revisions=-20% | GrowthEPS=+16.5% | GrowthRev=+291.4%
[Analyst] Revisions Ratio: -69%